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ObjectiveaaGenetic variation in the serotonin-2C receptor encoded by the HTR2C gene is one of the genetic determinants of antipsy-
chotic-induced weight gain. Peroxisome proliferator-activated receptors are nuclear receptors regulating the expression of genes involved 
in lipid and glucose metabolism. In this cross-sectional study, we investigated whether HTR2C-759C/T, HTR2C-697G/C, PPARα V227A, 
and PPARγ 161C/T genotypes were associated with metabolic syndrome (MetS) in patients with schizophrenia taking clozapine.
MethodsaaOne hundred forty-six Korean patients using clozapine for more than one year were genotyped for the HTR2C-759C/T, HTR2C-
697G/C, PPARα V227A, and PPARγ 161C/T polymorphisms, and their weight, waist circumference, blood pressure, triglycerides, high-den-
sity lipoprotein-cholesterol, total cholesterol, and glucose were measured. We used the criteria for MetS proposed by the National Choles-
terol Education Program-adapted Adult Treatment Panel III.
ResultsaaThe prevalence of MetS was 47.3% and was similar among men (49%) and women (42.9%). We found no significant differenc-
es between patients with and without MetS in terms of genotypes or allele frequencies. Logistic regression analyses also revealed no asso-
ciation between MetS and each genotype.
ConclusionaaWe did not find significant associations between four polymorphisms (HTR2C-759C/T, HTR2C-697G/C, PPARα V227A, 
and PPARγ 161C/T) and MetS in patients with schizophrenia taking clozapine.  Psychiatry Investig 2011;8:262-268
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INTRODUCTION
Clozapine is known to cause the most severe metabolic ad-
verse effect among antipsychotics. Clozapine appears to have 
the greatest potential to induce weight gain.
1 In a naturalistic 
study, 36.6% of patients who treated with clozpine for at least 
1 year were diagnosed with diabetes during the 5-year follow-
up.
2 In addition, clozapine has been linked to hypertriglyceri-
demia,
3 hypercholesterolemia
3,4 and associated with decrease 
in high-density lipoprotein (HDL) cholesterol.
5 Long-term 
clozapine treatment has been associated with increased rates 
of hypertension.
6
Metabolic syndrome (MetS) represents a constellation of 
cardiovascular risk factors that includes central obesity, dyslip-
idemia, hyperglycemia, and hypertension.
7 Subjects with MetS 
face substantially increased risks for the development of diabe-
tes
8 and cardiovascular disease.
9 Data obtained in various 
countries have shown that the prevalence of MetS in patients 
with schizophrenia ranged from 37% to 63% and that the rel-
ative risk for the MetS was 2-3 times greater among patients 
with schizophrenia than among the general population.
10
Insulin resistance plays a key role as the pathogenesis of 
MetS.
11 The current concept of the development of MetS is 
that environmental factors add to an underlying genetic pre-SH Kang et al. 
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ponderance to insulin resistance.
12 The mechanism behind 
MetS in schizophrenia is not entirely clear. The high interindi-
vidual variability suggests that genetic make-up is a modulat-
ing factor.
Genetic variation in the serotonin 2C (5HT2C) receptor en-
coded by the HTR2C gene is one of the genetic determinants 
of antipsychotic-induced weight gain. Yuan et al.
13 found that 
several polymorphisms in the promoter region of the HTR2C 
gene were associated with an increased risk of diabetes and 
obesity in patients with psychiatric disorders. Reynolds et 
al.
14,15 and Ellingrod et al.
16,17 found a positive association be-
tween the HTR2C -759C/T genotype and antipsychotic-in-
duced weight gain. Mulder et al.
18 found a positive association 
between the HTR2C -697G/C genotype and MetS in patients 
with schizophrenia.
Peroxisome proliferator-activated receptors (PPARs) are nu-
clear receptors regulating the expression of genes involved in 
lipid and glucose metabolism. The primary role of PPARs is to 
regulate the oxidation of fat within cells. PPARs increases fatty 
acid uptake into cells, enhance burning of fat by beta-oxida-
tion, and activate uncoupling proteins
19 which facilitates the 
disposal of fat in states of overabundance.
Excessive fatty acid storage is one of the mechanisms for in-
sulin resistance. PPARs improve insulin sensitivity due to re-
move the excessive fatty acid from muscle. They are encoded 
by 3 distinct genes: PPARα, PPARγ, PPARδ. PPARα is mainly 
expressed in tissues in which fatty acid catabolism is impor-
tant, such as the liver, kidney, heart, and muscle. The PPARγ 
gene is highly expressed in adipose tissue, where it controls 
adipocyte differentiation and lipid storage, and modulates the 
action of insulin.
Several reports on the association between PPARs polymor-
phisms and metabolic disturbances have been published. One 
of the frequently occurring PPARγ polymorphisms is C-to-T 
substitution in exon 6, which was identified in 1998 by Mei-
rhaegue et al. and has been studied in relation to obesity, glu-
cose intolerance, and cardiovascular risk.
20-23 To date, only a 
few studies on the association of this polymorphism with 
MetS and its components have been conducted, and the re-
sults are controversial. Many polymorphisms of the PPARα 
gene, especially the PPARα-V227A polymorphism in East 
Asians, have recently been described. This polymorphism has 
been studied in relation to the serum lipid concentration in 
the Asian population.
24,25 
A study conducted by Arulmozhi et al.
26 showed that PPARα 
and PPARγ agonists significantly reversed the increase in tri-
glycerides observed in response to antipsychotic drugs. These 
medications also reduced increases in insulin resistance and 
glucose levels for at least some of the antipsychotics.
26
The objective of this cross-sectional study was to evaluate 
whether the polymorphisms HTR2C-759C/T, HTR2C-697G/
C, PPARγ 161C/T, and PPARα V227A were associated with 
MetS in patients with schizophrenia taking clozapine.
METHODS
Subjects
This study was conducted from October 2007 to September 
2008 at the outpatient and inpatient departments of Seoul Na-
tional Hospital in Korea. The sample included patients diag-
nosed with schizophrenia who were 18-65 years of age and 
who had been taking clozapine for more than one year. All 
subjects had taken other antipsychotic medications before clo-
zapine. The DSM-IV diagnosis
27 was established by chart re-
view, and no exclusion criteria for concomitant psychotropic 
or medical pharmacology were applied. All subjects provided 
written informed consent for the study procedures, which 
were approved by the institutional review board at Seoul Na-
tional Hospital.
Data were collected on age, sex, duration of illness, current 
Clinical Global Impression-Severity score and number of cig-
arettes smoked daily. Data on the dosages and duration of cur-
rent antipsychotics and the number of concomitant psycho-
tropic medications were obtained from medical records. 
Information on the presence of and current medication regi-
men for diabetes, hypertension, and dyslipidemia was gath-
ered via patient self-reports.
Body weight and height were measured using standard hos-
pital scales and height measurement procedures while subjects 
wore light clothing without shoes. Body mass index (BMI) was 
calculated by weight (kg)/height (m
2). Waist circumference 
was measured from the narrowest point between the lower bor-
der of the rib cage and the iliac crest after a modest expiration. 
Blood pressure was measured in the sitting position after a 10-
min rest period. Fasting blood samples were taken in the mor-
ning after an 8-h overnight fast. Fasting plasma glucose, total 
cholesterol, triglycerides, and HDL cholesterol were measured 
in a central certified laboratory.
The present study used the criteria for MetS proposed by the 
National Cholesterol Education Program adapted Adult Treat-
ment Panel III (ATP IIIA),
28 which defined this condition as the 
presence of three or more of the following risk factors: central 
obesity; hypertriglyceridemia, with fasting plasma triglycer-
ides of ≥150 mg/dL; low HDL cholesterol with fasting HDL 
cholesterol of <40 mg/dL in men and <50 mg/dL in women; 
hypertension, with systolic and/or diastolic blood pressure of 
≥130/85 mmHg or known treatment for hypertension; and 
hyperglycemia, with fasting plasma glucose of ≥100 mg/dL or 
known treatment for diabetes. We used the definition of ab-
dominal obesity for Asian populations: ≥90 cm in men and 264  Psychiatry Investig 2011;8:262-268
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≥80 cm in women from the Western Pacific regional office of 
the World health organization.
29
Genotyping
Approximately 5 mL of venous blood was collected from ea-
ch subject in an ethylenediaminetetraacetic acid tube. Both 
HTR2C-759C/T (rs3813928) and HTR2C-697G/C (rs518147) 
polymorphism were genotyped by the sequencing method 
and both PPARγ 161C/T (rs3856806) and PPARα V227A 
(rs2016520) were analyzed by the SNaPshot assay.
DNA direct sequencing
Genomic DNA was prepared from peripheral blood samples 
using a nucleic acid isolation device, QuickGene-mini80 (FU-
JIFILM, Tokyo, Japan). The Polymerase chain reaction (PCR) 
method was used to amplify those fragments by using UCSC 
In-Silico PCR (http://genome.ucsc.edu/cgi-bin/hgPcr? com-
mand=start). The final volume of the PCR was 10 mL, consist-
ing of 10 ng of DNA, 0.0005 mM of each primer pair, 0.25 
mM dNTPs, 3 mM MgCl2, 1 mL 1×reaction buffer, and 0.25U 
Taq DNA polymerase (Intron Biotechnology, Seongnam-Si, 
Gyeonggi-do, Korea). To amplify exon 1, the 500 mM of beta-
ine was added to the PCR system, which was different with 
exons 2, 3, and 4. The PCR conditions used were as follows: 
initial denaturation at 94°C for 5 min, followed by 35 cycles 
of denaturation at 94°C for 30 s, annealing at 60-65°C for 30 
s, initial extension at 72°C for 30-60 s, and final extension at 
72°C for 10 min. The PCR products were purified using a 
MultiScreen384-PCR Filter Plate (Milipore, Billerica, MA, 
USA). The purified products were then sequenced using a 
BigDye Terminator Cycle Sequencing Kit and an ABI 3730xl 
automated sequencer (Applied Biosystems, Foster City, CA, 
USA). The sequencing primers were the same as those used 
for the PCR amplification. Mutation analyses were performed 
using Phred, Phrap, Consed, Polyphred 5.04 software (http://
droog.mbt.washington.edu/PolyPhred.html).
SNaPshot assay
Genomic DNA was extracted using a SNaPshot Multplex 
kit (Foster City, CA, USA). The SNaPshot assay was performed 
according to the manufacturer’s instructions (ABI PRISM SNa-
PShot Multiplex kit, Foster City, CA, USA). Analysis was car-





N 146 77 69 (47.3%)
Age 039.8±8.5 038.4±8.2 041.3±5.6 0.05 0.044
Sex, N
Male 104 (71.2%) 53 51 (49%) χ
2=0.46 0.584
Female 42 (28.8%) 24 18 (42.9%)
Age of onset, (years) 020.7±5.2 020.1±4.9 021.3±5.5 2.02 0.171
Duration of illness, years 019.0±7.5 018.3±7.7 019.8±7.3 0.02 0.210
Clinical Global Impression-Severity 003.7±0.8 003.7±0.8 003.8±0.8 0.30 0.709
Smokers, N (%) 94 (64.4%) 044 (57.1%) 050 (72.5%) 3.73 0.059
Number of cigarettes smoked daily 016.7±10.1 014.2±9.4  018.9±10.3 0.06 0.024
Body mass index, kg/m
2 024.4±4.6 022.7±3.9 026.7±4.5 1.02 <0.001
Dosage of clozapine, mg/day 417.5±133.4 423.4±139.7 410.9±126.7 1.02 0.572
Duration of clozapine, months 051.4±31.2 048.3±28.4 054.8±33.8 3.35 0.209
Number of concomitant psychotropic medications 001.9±1.5 002.0±1.6 001.9±1.5 0.08 0.648
Presence of Mood stabilizer
Valproate 67 (45.9%) 37 (48.1%) 30 (43.5%) 0.31 0.349
Lithium 12 (8.2%) 5 (6.5%) 7 (10.1%) 0.64 0.309
Topiramate 9 (6.2%) 5 (6.5%) 4 (5.8%) 0.03 0.569
Type of antipsychotics (AP), N (%)
Clozapine  93 (63.7%) 48 45 χ
2=2.00 0.573
Clozapine+Typical AP  40 (27.4%) 20 20
Clozapine+Atypical AP 12 (8.2%) 8 4
Clozapine+Typical+Atypical AP 1 (0.7%) 1SH Kang et al. 
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ried out using Genemapper software (version 3.0; Applied 
Biosystems).
Statistical analyses
Demographic and clinical characteristics of subjects were 
summarized using a descriptive procedure. All continuous 
variables were presented as means with standard deviations; 
they were compared between two groups using an indepen-
dent t-test. Group differences in categorical variables were ex-
amined using the chi-square test.
The genotype distribution was tested for Hardy-Weinberg 
equilibrium by HAPANALYZER software (available at http://
hap.ngri.go.kr/)
30 based on chi-squared analysis, prior to asso-
ciation analyses. Associations between each polymorphism 
and MetS were analyzed using a multiple logistic regression 
analysis adjusted for potential confounding effects of age, sex, 
type of antipsychotics, dosage and duration of clozapine, pres-
ence of mood stabilizers (valproate, lithium, topiramate) and 
number of cigarettes smoked daily. Common allele was con-
sidered as a reference. A p-value of <0.05 was considered to be 
statistically significant. We used the SPSS 12.0 version for 
Windows (SPSS Inc., Chicago, IL, USA) for analyses.
RESULTS
Of the total sample of 146 patients, 104 (71.2%) were men. 
All patients were of Korean ethnicity. The mean age was 
39.8±8.5 years (range: 21-62 years), and the mean duration of 
illness was 19.0±7.5 years (range: 3-37 years). The mean clo-
zapine dosage was 417.5±133.4 mg/day, and the mean dura-
tion of clozapine use was 51.4±31.2 months. The mean age of 
onset was significantly younger in male than in female patients 
(19.9±4.9 vs. 22.6±5.6, p=0.005) and the mean clozapine dos-
age was higher in male than female patients (432.3±140.1 vs. 
381.0±108.3, p=0.035). More than half (63.7%) had been tak-
ing a clozapine for more than one year and the rest had been 
taking other antipsychotics with clozapine for more than one 
year. More than half (64.4%) of the sample currently smoked, 
and the smoking rate was significantly higher in men than in 
women (76% vs. 35.7%, χ
2=21.1, p<0.001).
According to the ATP IIIA, the prevalence of MetS among 
these patients was 47.3% and was similar among men (49%) 
and women (42.9%). When comparing with patients without 
MetS, patients with MetS were significantly older (41.3±5.6 vs. 
38.4±8.2, p=0.044) and had significantly higher number of 
cigarettes smoked per day (18.9±10.3 vs. 14.2±9.4, p=0.024) 
Table 2. Comparison of genotype and allele frequencies of polymorphisms with presence of metabolic syndrome




Negative, N Positive, N
HTR2C -759C/T rs3813928 Genotypes CC/C 64 54 3.10 0.212
CT 5 3
TT/T 6 12
Alleles C 86 70 1.01 0.122
T 11 17
HTR2C -697G/C rs518147 Genotypes GG/G 64 52 2.95 0.229
GC 5 3
CC/C 8 14
Alleles G 88 68 2.01 0.103
C 13 19
PPARα V227A rs1800234 Genotypes TT 71 63 0.04 0.539
CT 6 6
Alleles T 148 132 0.03 0.846
C 6 6
PPARγ 161C/T rs3856806 Genotypes CC 59 53 0.01 0.996
CT 17 15
TT 1 1
Alleles C 135 121 1.07 0.996
T 19 17
HTR2C: serotonin 2C receptor, PPARα: peroxisome proliferator-activated receptor α gene, PPARγ: peroxisome proliferator-activated recep-
tor γ gene, SNP: single nucleotide polymorphism266  Psychiatry Investig 2011;8:262-268
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and higher BMI (26.7±4.5 vs. 22.7±3.9, p<0.001)(Table 1).
All genotypes were in Hardy-Weinberg equilibrium with 
non-significant χ
2 values with respect to comparisons between 
the observed and expected genotype frequencies of each of the 
tested polymorphisms [(-759C/T)(p=0.215), (-697G/C)
(p=0.198), (161C/T)(p=1.0), (V227A)(p=1.0)]. No significant 
differences in genotypes or allele frequencies between patients 
with and without MetS were observed (Table 2). Logistic re-
gression analyses also showed no associations between MetS 
and each genotype (Table 3).
DISCUSSION
This study found no association between four polymor-
phisms (HTR2C-759C/T, HTR2C-697G/C, PPARα V227A, 
and PPARγ 161C/T) and MetS in patients with schizophrenia 
taking clozapine for more than 1 year.
Mulder et al. reported that several HTR2C polymorphisms 
were associated with MetS in patients taking various antipsy-
chotics. In one report, the HTR2C-697G/C polymorphism 
was associated with MetS,
18 but no significant association was 
found in a study attempting to replicate these results.
31 Consis-
tent with the results of our study, previous studies have shown 
that the HTR2C-759C/T polymorphism, which is known to 
be associated with antipsychotic-induced weight gain,
14-16 had 
no association with MetS.
18,31,32 Another polymorphism of 
HTR2C (rs1414334) has been reported to be significantly as-
sociated with MetS in patients with schizophrenia,
18,31,32 and 
this association has been particularly strong in patients using 
clozapine and risperidone, which have both high affinity for 
the 5-HT2C receptor.
31 All subjects enrolled in our study had 
been taking clozapine; despite this methodological advantage, 
the -697G/C and -759C/T polymorphisms of HTR2C had no 
significant association with MetS. In another study, the -697G/
C and -759C/T polymorphisms of HTR2C were not associat-
ed with levels of insulin, triglycerides, and cholesterol in pa-
tients treated with olanzapine or clozapine.
33
The common polymorphisms of PPAR, PPARα V227A, and 
PPARγ 161C/T, also had no significant association with MetS 
in patients with schizophrenia. The presence of the A227 allele 
was associated with lower serum concentrations of total cho-
lesterol and triglycerides in women, but not in men.
25 Our study 
did not include a sufficient number of female patients, and 
only two female participants had the C allele of V227A. Oth-
er reports have described the association of the PPARα 
V227A polymorphism with serum lipid concentrations ac-
cording to age, drinking habits, and exercise status in Japanese 
individuals,
24,34 but we did not consider exercise and dinking 
status. One previous study reported that the PPARγ 161C/T 
polymorphism had no association with the overall prevalence 
of MetS, but that a decrease in the HDL-cholesterol compo-
nent was less prevalent in normal female subjects with the T 
allele.
35 In our study, relatively few female patients had the T 
allele of 161C/T (n=11).
The association between PPAR polymorphisms and meta-
bolic disturbances has been investigated primarily in normal 
populations or patients with diabetes. To date, only one study 
on PPAR polymorphisms in patients with schizophrenia has 
been published, and this study focused on the association of 
olanzapine-induced weight gain and PPARγ Pro12Ala poly-
morphism in patients with schizophrenia.
36 Our study is the 
first to focus on the association of PPAR polymorphisms with 
MetS in patients with schizophrenia. Although PPAR poly-
morphisms have not been associated with the prevalence of 
MetS, the association between individual metabolic compo-
nents and these polymorphisms needs to be investigated.
Several reports on the prevalence of MetS in Korean pa-
tients with schizophrenia have emerged,
37,38 and the present 
study is the first to investigate the prevalence of MetS in sub-
jects who were treated with one kind of antipsychotic medica-
tion, clozapine. We found that 47.3% of the Korean patients 
with schizophrenia taking clozapine met the criteria for MetS, 
which is comparable to the prevalence rates reported in stud-
ies of MetS among European (50%)
39 and US (53.8%) patients 
with schizophrenia taking clozapine.
40 We thus confirmed the 
high prevalence of MetS in patients with schizophrenia taking 
clozapine.
There are several limitations in this study. First, the sample 
Table 3. Logistic analysis of polymorphisms with the risk of metabolic syndrome
SNP† Codominant Dominant Recessive
OR (95% CI)* p OR (95 % CI)* p OR (95 % CI)* p
HTR2C -759C/T 1.53 (0.89-2.62) 0.122 1.81 (0.71-4.62) 0.216 2.75 (0.89-8.53) 0.080
HTR2C -697G/C 1.49 (0.91-2.44) 0.114 1.81 (0.75-4.35) 0.185 2.49 (0.89-6.98) 0.082
PPARα V227A 0.92 (0.24-3.51) 0.898 0.92 (0.24-3.51) 0.898 - -
PPARγ 161C/T 1.03 (0.47-2.22) 0.950 1.02 (0.44-2.36) 0.972 1.19 (0.07-21.3) 0.908
*data were adjusted for age, sex, type of antipsychotics, dosage and duration of clozapine, presence of mood stabilizers (valproate, lithium, 
topiramate) and number of cigarettes smoked per day, †data were analyzed with the common genotype as the reference for all polymorphisms. 
SNP: single nucleotide polymorphism, CI: confidence interval, OR: odds ratioSH Kang et al. 
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was relatively small; thus, a more extended study with a larger 
population is needed. Second, because this study used a cross-
sectional design, we could not evaluate the causal relationships 
between MetS and clozapine. Data on metabolic parameters of 
the patients at the initiation of clozapine treatment were not 
available to us. Therefore it was not possible to analyze data for 
change in these parameters over time related to the use of clo-
zapine. Henderson et al.
2 reported that clozapine-induced wei-
ght gain continued until approximately 46 months following 
initiation of clozapine treatment, after which weight gain ap-
peared to level off. Therefore the duration of the clozapine tre-
atment in this study (51.4 months) may have been sufficient to 
determine the metabolic adverse effects of this medication. Thi-
rd, several variables other than genetic factors can contribute 
to the risk of MetS. Although we considered the factors that 
are typically associated with potential influence on metabolic 
states, such as smoking and mood stabilizers, we failed to in-
clude other parameters, such as physical activity, diet and 
other medications which might cause weight gain.
Our results show that the HTR2C-759C/T, HTR2C-697G/
C, PPARα V227A, and PPARγ 161C/T SNPs were not associ-
ated with MetS in patients with schizophrenia taking clozap-
ine. The possibility that these SNPs may serve as risk markers 
for metabolic adverse effects should be the subject of further 
examination.
Acknowledgments
This study was supported by the Choi Shin Hae Korean Foundation of 
Neuropsychiatric Research. We are particularly grateful to Ka Hee Lee, 
Gwon Young Kang, Kyong Hoon Kim, Kwon Kon Kim, Minah Soh, Min 
Young Sim, Hwang Bin Lee for helping with data collection and to Tae 
Kyung Lee, Hae Ree Han, Dong Yeon Park for advising on study design 
and analyses.
REFERENCES
1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante 
MC et al. Antipsychotic-induced weight gain: a comprehensive research 
synthesis. Am J Psychiatry 1999;156:1686-1696.
2. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoen-
feld DA et al. Clozapine, diabetes mellitus, weight gain, and lipid abnor-
malities : A five-year naturalistic study. Am J Psychiatry 2000;157:975-
981.
3. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB et al. Effects of typ-
ical and atypical antipsychotics on glucose-insulin homeostasis and lip-
id metabolism in first-episode schizophrenia. Psychopharmacology 
(Berl) 2006;186:572-578.
4. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy 
JP et al. Changes in glucose and cholesterol levels in patients with 
schizophrenia treated with typical or atypical antipsychotics. Am J Psy-
chiatry 2003;160:290-296.
5. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. 
The effects of novel antipsychotics on glucose and lipid levels. J Clin 
Pyschiatry 2002;63:856-865.
6. Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden 
D. Clozapine and hypertension : a chart review of 82 patients. J Clin Psy-
chiatry 2004;65:686-689.
7. Reaven GM. Role of insulin resistance in human disease. Nutrition 1997; 
13:65.
8. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern 
MP. Prospective analysis of the insulin-resistance syndrome (syndrome 
X). Diabetes 1992;41:715-722.
9. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Car-
diovascular morbidity and mortality associated with the metabolic syn-
drome. Diabetes Care 2001;24:683-689.
10. Correll CU. Balancing efficacy and safety in treatment with antipsychot-
ics. CNS Spectr 2007;12(10 Suppl 17):12-20,35.
11. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tu-
omilehto J et al. The metabolic syndrome and total and cardiovascular 
disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
12. Hong Y, Pedersen NL, Brismar K, de Faire U. Genetic and environmen-
tal architecture of the features of the insulin-resistance syndrome. Am J 
Hum Genet 1997;60:143-152.
13. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. 
Identification of polymorphic loci in the promoter region of the sero-
tonin 5-HT2C receptor gene and their association with obesity and type 
II diabetes. Diabetologia 2000;43:373-376.
14. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-
induced weight gain with a 5-HT2C receptor gene polymorphism. 
Lancet 2002;359:2086-2087.
15. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter re-
gion of the serotonin 5-HT(2C) receptor gene and clozapine-induced 
weight gain. Am J Psychiatry 2003;160:677-679.
16. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F 
et al. Weight gain associated with the-759C/T polymorphism of the 
5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr 
Genet 2005;134B:76-78.
17. Miller DD, Ellingrod VL, Holman TL, Buckley PF, Arndt S. Clozapine-
induced weight gain associated with the 5HT2C receptor-759C/T poly-
morphism. Am J Med Genet B Neuropsychiatr Genet 2005;133B:97-
100.
18. Mulder H, Franke B, van der-Beek van der AA, Arends J, Wilmink FW, 
Scheffer H, et al. The association between HTR2C gene polymorphisms 
and the metabolic syndrome in patients with schizophrenia. J Clin Psy-
chopharmacol 2007;27:338-343.
19. Luquet S, Lopez-Soriano J, Holst D, Gaudel C, Jehl-Pietri C, Fredenrich 
A et al. Roles of peroxisome proliferator-activated receptor delta 
(PPARdelta) in the control of fatty acid catabolism. A new target for the 
treatment of metabolic syndrome. Biochimie 2004;86:833-837.
20. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J et 
al. A genetic polymorphism of the peroxisome proliferator-activated re-
ceptor gamma gene influences plasma leptin levels in obese humans. 
Hum Mol Genet 1998;7:435-440.
21. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS et 
al. Two polymorphisms in the peroxisome proliferator-activated recep-
tor-gamma gene are associated with severe overweight among obese 
women. J Clin Endocrinol Metab 1999;84:3708-3712.
22. Poulsen P, Andersen G, Fenger M, Hansen T, Echwald SM, Vølund A et 
al. Impact of two common polymorphisms in the PPARgamma gene on 
glucose tolerance and plasma insulin profiles in monozygotic and dizy-
gotic twins: thriffy genotype, thriffy phenotype, or both? Diabetes 2003; 
52:194-198.
23. Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated re-
ceptor gamma C161-->T polymorphism and coronary artery disease. 
Cardiovasc Res 1999;44:588-594.
24. Naito H, Kamijima M, Yamanoshita O, Nakahara A, Katoh T, Tanaka N 
et al. Differential effects of aging, drinking and exercise on serum cho-
lesterol levels dependent on the PPARA-V227A polymorphism. J Occup 
Health 2007;49:353-362.
25. Chan E, Tan CS, Deurenberg-Yap M, Chia KS, Chew SK, Tai ES. The 
V227A polymorphism at the PPARA locus is associated with serum lip-
id concentrations and modulates the association between dietary poly-268  Psychiatry Investig 2011;8:262-268
Polymorphisms in HTR2C and PPARs and Metabolic Syndrome
unsaturated fatty acid intake and serum high density lipoprotein con-
centrations in Chinese women. Atherosclerosis 2006;187:309-315.
26. Arulmozhi DK, Dwyer DS, Bodhankar SL. Antipsychotic induced met-
abolic abnormalities : an interaction study with various PPAR modula-
tors in mice. Life Sci 2006;79:1865-1872.
27. American Psychiatric Association. Diagonstic and Statistical Manual of 
Mental Disorders, Fourth Edition. Washington, DC: American Psychi-
atric Press; 1994.
28. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin 
BA et al. Diagnosis and management of the metabolic syndrome : an 
American Heart Association/National Heart, Lung, and Blood Institute 
Scientific Statement. Circulation 2005;112:2735-2752.
29. World Health Organization. The Asia-Pacific Perspective: Redefing Obe-
sity And Its Treatment. Sydney: Health Communication Australia, 2000, 
p.15-21.
30. Jung HY, Park JS, Park YJ, Kim YJ, Kimm K, Koh IS. HapAnalyzer : 
minimum haplotype analysis system for association studies. Genomics 
Inform 2004;2:107-109.
31. Mulder H, Cohen D, Scheffer H, Gispen-de Wied C, Arends J, Wilm-
ink FW et al. HTR2C gene polymorphisms and the metabolic syndrome 
in patients with schizophrenia: a replication study. J Clin Psychophar-
macol 2009;29:16-20.
32. Risselada AJ, Vehof J, Bruggeman R, Wilffert B, Cohen D, Al Hadithy 
AF et al. Association between HTR2C gene polymorphisms and the 
metabolic syndrome in patients using antipsychotics: a replication study. 
Pharmacogenomics J 2010: in pressing.
33. Gunes A, Melkersson KI, Scordo MG, Dahl ML. Association between 
HTR2C and HTR2A polymorphisms and metabolic abnormalities in 
patients treated with olanzapine or clozapine. J Clin Psychopharmacol 
2009;29:65-68.
34. Naito H, Yamanoshita O, Kamijima M, Katoh T, Matsunaga T, Lee CH 
et al. Association of V227A PPARalpha polymorphism with altered se-
rum biochemistry and alcohol drinking in Japanese men. Pharmaco-
genet Genomics 2006;16:569-577.
35. Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH et al. Effects of two 
common polymorphisms of peroxisome proliferator-activated receptor-
gamma gene on metabolic syndrome. Arch Med Res 2006;37:86-94.
36. Herken H, Erdal M, Aydin N, Sengul C, Karadag F, Barlas O et al. The 
association of olanzapine-induced weight gain with peroxisome prolif-
erator-activated receptor-gamma2 Pro12Ala polymorphism in patients 
with schizophrenia. DNA Cell Biol 2009;28:515-519.
37. Nam YY, Kim CS, Ahn CW, Park KM, Ryu B, Kim CH. Clinical corre-
lates of metabolic syndrome in patients with chronic schizophrenia. Ko-
rean J Psychopharmacol 2006;17:335-341.
38. Jeong JT, Yoon BH, Kim TU, Sea YH, Park SH, Jeong KY et al. Preva-
lence of metabolic syndrome in chronic schizophrenic inpatients. Kore-
an J Schizophr Res 2009;12:83-89.
39. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S et al. 
Typical and atypical antipsychotics differentially affect long-term inci-
dence rates of the metabolic syndrome in first-episode patients with 
schizophrenia: a retrospective chart review. Schizophr Res 2008;101: 
295-303.
40. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X et al. Prev-
alence of the metabolic syndrome among patients receiving clozapine. 
Am J Psychiatry 2006;163:1273-1276.